Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up

Ad

Investor Relations

MIRA Stock - MIRA Pharmaceuticals Stock Trading

home / stock / mira

MIRA MIRA Quote MIRA Short MIRA News MIRA Articles MIRA Message Board

About | MIRA Pharmaceuticals Inc. (NASDAQ:MIRA)

MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.

Quote | MIRA Pharmaceuticals Inc. (NASDAQ:MIRA)

Last:$1.17
Change Percent: -0.93%
Open:$1.09
Close:$1.17
High:$1.2
Low:$1.07
Volume:416,014
Last Trade Date Time:03/18/2025 03:00:00 am

News | MIRA Pharmaceuticals Inc. (NASDAQ:MIRA)

  • MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development

    MIAMI, FLORIDA / ACCESSWIRE / December 19, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a preclinical-stage pharmaceutical company focused on developing therapies for neurological and neuropsychiatric disorders, today announced that it has submitted an Investigational New Drug (IND) applicat...

    • December 19, 2024 09:00:00 am

    • |
    • ACCESSWIRE
    • |
      • MIRA Stock
      • MIRA Quote
      • MIRA Short
      • MIRA News
      • MIRA Articles
      • MIRA Message Board
  • MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End

    Strong Safety Profile Validated Across Studies, Setting the Stage for Clinical Trials in Neuropathic Pain MIAMI, FL / ACCESSWIRE / December 10, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a preclinical-stage pharmaceutical company, proudly announces the successful completion of its cur...

    • December 10, 2024 08:30:00 am

    • |
    • ACCESSWIRE
    • |
      • MIRA Stock
      • MIRA Quote
      • MIRA Short
      • MIRA News
      • MIRA Articles
      • MIRA Message Board

Message Board Posts | MIRA Pharmaceuticals Inc. (NASDAQ:MIRA)

Subject By Source When
No posts yet.
Stock Information
Get MIRA Alerts

News, Short Squeeze, Breakout and More Instantly...

MIRA Pharmaceuticals Inc. Company Name:

MIRA Stock Symbol:

NASDAQ Market:

-0.93% G/L:

$1.17 Last:

416,014 Volume:

$1.09 Open:

$1.17 Close:

MIRA Pharmaceuticals Inc. Website:

MIRA Pharmaceuticals Inc. Logo

Ad

Investor Relations
RECENT MIRA NEWS
  • MIRA - MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development

    MIAMI, FLORIDA / ACCESSWIRE / December 19, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a preclinical-stage pharmaceutical company focused on developing therapies for neurological and neuropsychiatric disorders, today announced that it has submitted an Investigational New Drug (IND) applicat...

  • MIRA - MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End

    Strong Safety Profile Validated Across Studies, Setting the Stage for Clinical Trials in Neuropathic Pain MIAMI, FL / ACCESSWIRE / December 10, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a preclinical-stage pharmaceutical company, proudly announces the successful completion of its cur...

  • MIRA - Expected earnings - MIRA Pharmaceuticals Inc.

    MIRA Pharmaceuticals Inc. (MIRA) is expected to report $-0.18 for Q3 2024

  •
  • Research
  • Stock Search
  • News Releases
  • Articles
  • Topics
  • Message Boards
  • Trending Stocks
  • Trending Feed
  • Trending Alerts
  • Watchlist
  • Short Information
  • Stock Wall
  • Link Twitter
  • Sign Up
  • Login
  • Contact

Link your X Account

Link your X Account to Market Wire News

When you linking your X Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your X account.

Be alerted of any news about your stocks and see what other stocks are trending.

Trending Stock Alerts

Trending Stock Alerts

Our Next Stock Alert could be Coming in Minutes!

Sign Up Today To Get Full Access To Our Next Stock Report!

  • Day Before Email and Text Notifications of New Alerts
  • Day of Email and Text Notifications
  • Trending Stocks, Watchlist and News Releases
  • Mobile App Notifications
Trending Stock Alerts

Get MIRA Alerts

Get MIRA Alerts

News, Short Squeeze, Breakout and More Instantly...

Sign up or login to continue

Sign up or login to continue.

Forgot password?


Mobile Number Subscribers

Market Wire News provides notifications to customers about updates, service, reminders, or products. Current and new customers of Market Wire News will enter their mobile numbers on a web opt-in form https://marketwirenews.com. Supported Carriers are as follows Alltel, AT&T, Cincinnati Bell, Dobson Cellular Systems, Inter Op, MetroPCS®, Nextel Communications, Sprint PCS, T-Mobile®, U.S. Cellular®, Verizon Wireless, and Virgin Mobile U.S. T-Mobile® is not liable for delayed or undelivered messages. There are no premium charges for joining Market Wire News service. Message and data rates may apply. Subscribers to Market Wire News service may receive up to 500 per month.

How to Opt Out

To opt-out of the Market Wire News program, send or text STOP, END, QUIT, CANCEL or UNSUBSCRIBE to (844) 931-3999. An unsubscribe message will be sent to your number confirming the cancellation, but no more messages will be sent after that one.

Mobile Support

For support or information about a Market Wire News, send or text HELP to (844) 931-3999. Optionally, you may email support@marketwirenews.com.

Disclaimer

This electronic content is for the purposes of solicitation subscriptions for Market Wire News. Market Wire News expects to generate new advertisement revenue resulting from the distribution of this electronic content. The amount of which is unknown at this time. Market Wire News is not a registered investment adviser or broker-dealer. This electronic content does not provide a professional analysis of a any stock financial position. any stock's financial position and all other information regarding the featured Company should be verified directly with any stock. This electronic content is provided as an information service only, and any statements and opinions in this electronic content should not be construed as an offer or solicitation to buy or sell any security. Market Wire News accepts no liability for any loss arising from an investor's reliance on or use of this electronic content. An investment in any company is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Market Wire News does not own, buy, sell or plans to own, buy, sell, and of any stock's shares. This electronic content contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Please read our full disclaimer for compensation and more detailed information.

Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Log In

Sign Up

Stay Connected

| X

| Facebook

| BlueSky

| LinkedIn

| Telegram

| Discord

Contact

Privacy

Terms of Service

Disclaimer

© 2025 Market Wire News 1